LURIE CANCER CENTER
Multidisciplinary Head & Neck Symposium

November 10-11, 2018

The Lurie Cancer Center Multidisciplinary Head & Neck Symposium is a one and one-half day interactive program on the diagnosis, treatment and rehabilitation of head and neck cancer patients. The symposium brings together medical oncologists, radiation oncologists, otolaryngologists, head and neck surgeons, dentists, nurses and allied health professionals to discuss and debate the latest advances in multidisciplinary therapies, clinical research and supportive care methodology. The agenda features internationally-recognized experts who will engage attendees in dialogue to improve multi-specialty collaboration in the treatment and care of head and neck cancer patients.

Register by August 31 for early bird discount; prices increase September 1.

cancer.northwestern.edu/headneck

LEARNING OBJECTIVES

1. Apply a multidisciplinary approach to the treatment of head and neck cancer.
2. Assess state-of-the-art therapeutic options for the treatment of head and neck cancer including:
   i. Minimally invasive surgical treatment including robotic surgery, image-guided skull base surgery, and sentinel lymph node mapping.
   ii. Novel radiation delivery methods including proton beam therapy and image-guided radiation therapy (IGRT).
   iii. Incorporation of immunotherapy for treatment of advanced head and neck cancer.
3. Discuss future directions to the treatment of head and neck cancer based on the latest basic science and clinical developments including:
   i. The diagnosis and treatment of human papillomavirus (HPV) positive oropharyngeal.
   ii. The latest developments in the molecular biology of head and neck cancer and its impact on management.
   iii. The role of biomarkers in the contemporary management of head and neck cancer.
4. Discuss new staging guidelines (8th edition AJCC) for head and neck cancer.
5. Apply current treatment guidelines to patients with head and neck cancer.
6. Integrate quality measures for the care of head and neck cancer into their own clinical practice.
7:45 a.m. - Opening Remarks  
Sandeep Samant, MD

8:00 a.m. - Oropharynx Cancer I  
Moderator: Robert Haddad, MD
Risk Stratification in Oropharynx Cancer: Sue Yom, MD, PhD
Radiation Strategies for De-Intensification: Paul Harari, MD
Chemotherapeutic Considerations: A. Dimitrios Colevas, MD
Case Discussion: A. Dimitrios Colevas, MD; Paul Harari, MD; Randal Weber, MD; Sue Yom, MD, PhD

9:30 a.m. - Larynx Cancer  
Moderator: Gregory Wolf, MD
Organ Preservation Surgery for Larynx Cancer: Bruce Haughey, MD
Nonsurgical Organ Preservation: Robert Haddad, MD
Case Discussion: Robert Haddad, MD; Bruce Haughey, MD; Bharat Mittal, MD

10:30 a.m. - Break

10:45 a.m. - Oropharynx Cancer II  
Moderator: Sandeep Samant, MD
Risk Stratification after Surgery for Oropharynx Cancer, 8th Edition Staging: Bruce Haughey, MD
Innovations in Surgical Technique and Technology: Chris Holsinger, MD
Adjuvant Therapy in Oropharynx Cancer: Harry Quon, MD
Case Discussion: A. Dimitrios Colevas, MD; Bruce Haughey, MD; Chris Holsinger, MD; Harry Quon, MD

12:15 p.m. - Lunch

1:15 p.m. - Oral Cavity  
Moderator: Kerstin Stenson, MD
Sentinel Node Biopsy for Early Oral Cancer: Sandeep Samant, MD
Reconstruction for Advanced Oral Cancer: Urjeet Patel, MD
Prosthetic Rehabilitation for Mandibular Defects: Mark Hutten, DDS
Adjuvant Therapy for Oral Cancers: Timothy Kruser, MD
Case Discussion: Mark Hutten, DDS; Timothy Kruser, MD; Urjeet Patel, MD; Sandeep Samant, MD

2:15 p.m. - Thyroid  
Moderator: Ashok Shaha, MD
Molecular Diagnosis of Thyroid Nodules: Whitney Liddy, MD
Risk Stratification After Surgery and Indications of Radioactive Iodine Therapy: Peter Kopp, MD
Indications for EBRT in Thyroid Cancer: Sue Yom, MD, PhD
Case Discussion: Chris Holsinger, MD; Peter Kopp, MD; Whitney Liddy, MD; Sue Yom, MD, PhD

3:45 p.m. - Break

4:00 p.m. - Cutaneous Malignancies in Head and Neck Cancer  
Moderator: Randal Weber, MD
Management of Lymphatic Metastasis in Head Neck Melanoma: Jeffrey Wayne, MD
What’s New in the World of Cutaneous Head and Neck Malignancies: Sunandana Chandra, MD, MS
How Best to Utilize Mohs Surgery in Cutaneous Head Neck Cancer: Simon Yoo, MD
NMSC at the Skull Base: Radiation Therapy Versus Combined Therapy: Sue Yom, MD, PhD
Case Discussion: Sunandana Chandra, MD, MS; Jeffrey Sosman, MD; Jeffrey Wayne, MD; Sue Yom, MD, PhD; Simon Yoo, MD

4:55 p.m. - Adjourn

8:00 a.m. - Immunotherapy in Head and Neck Cancer  
Moderator: Jeffrey Sosman, MD
Advances in Immunotherapy for Cancer: Jeffrey Sosman, MD
Immunotherapy for Recurrent/Metastatic Head and Neck Cancer: Tanguy Seiwert, MD
Combining Immunotherapy with Radiotherapy: Zachary Morris, MD, PhD
Management of Adverse Effects with Immunotherapy: Jeffrey Sosman, MD
Question & Answer

9:30 a.m. - Unknown Primary Cancer  
Moderator: Urjeet Patel, MD
Modern Approaches for Identification of Unknown Primary: Chris Holsinger, MD
Avoiding Pitfalls in Pathologic Diagnosis: Borislav Alexiev, MD
Imaging for Unknown Primary Cancer: Achilles Karagianis, DO
We Identified the Primary, Now What? Harry Quon, MD
Case Discussion: Borislav Alexiev, MD; Chris Holsinger, MD; Achilles Karagianis, DO; Harry Quon, MD

10:45 a.m. - Boxed Lunch Break

11:00 a.m. - Head and Neck Oncology: Where Are We Now and Where Are We Going?  
Coverage from the 2018 ASCO Annual Meeting
Mark Agulnik, MD; A. Dimitrios Colevas, MD; Tanguy Seiwert, MD; Matthew Witek, MD

11:45 a.m. - Tumor Board: Paranasal Sinus, Nasopharynx, Salivary  
Moderator: Sandeep Samant, MD
Michelle Gentile, MD, PhD; Harry Quon, MD; Kerstin Stenson, MD; Victoria Villafior, MD; Randal Weber, MD

1:15 p.m. - Adjourn

FACULTY

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Agulnik, MD</td>
<td>Lurie Cancer Center</td>
</tr>
<tr>
<td>Borislav Alexiev, MD</td>
<td>Northwestern Medicine</td>
</tr>
<tr>
<td>Sunandana Chandra, MD, MS</td>
<td>Lurie Cancer Center</td>
</tr>
<tr>
<td>A. Dimitrios Colevas, MD</td>
<td>Stanford Cancer Center</td>
</tr>
<tr>
<td>Michelle Gentile, MD</td>
<td>Lurie Cancer Center</td>
</tr>
<tr>
<td>Robert Haddad, MD</td>
<td>Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td>Paul Harari, MD</td>
<td>University of Wisconsin Carbone Cancer Center</td>
</tr>
<tr>
<td>Bruce Haughey, MD</td>
<td>Florida Hospital Medical Group</td>
</tr>
<tr>
<td>Chris Holsinger, MD</td>
<td>Stanford Cancer Center</td>
</tr>
<tr>
<td>Mark Hutten, DDS</td>
<td>Northwestern Medicine</td>
</tr>
<tr>
<td>Achilles Karagianis, DO</td>
<td>Northwestern Medicine</td>
</tr>
<tr>
<td>Peter Kopp, MD</td>
<td>Lausanne University Medical School</td>
</tr>
<tr>
<td>Timothy Kruser, MD</td>
<td>Lurie Cancer Center</td>
</tr>
<tr>
<td>Whitney Liddy, MD</td>
<td>Northwestern Medicine</td>
</tr>
<tr>
<td>Bharat Mittal, MD</td>
<td>Lurie Cancer Center</td>
</tr>
<tr>
<td>Zachary Morris, MD, PhD</td>
<td>University of Wisconsin Carbone Cancer Center</td>
</tr>
<tr>
<td>Urjeet Patel, MD</td>
<td>Northwestern Medicine</td>
</tr>
<tr>
<td>Harry Quon, MD</td>
<td>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
</tr>
<tr>
<td>Sandeep Samant, MD</td>
<td>Northwestern Medicine</td>
</tr>
<tr>
<td>Tanguy Seiwert, MD</td>
<td>The University of Chicago Medicine</td>
</tr>
<tr>
<td>Ashok Shaha, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Kerstin Stenson, MD</td>
<td>Lurie Cancer Center</td>
</tr>
<tr>
<td>Jeffrey Sosman, MD</td>
<td>Northwestern Medicine</td>
</tr>
<tr>
<td>Victoria Villafior, MD</td>
<td>Lurie Cancer Center</td>
</tr>
<tr>
<td>Jeffrey Wayne, MD</td>
<td>Lurie Cancer Center</td>
</tr>
<tr>
<td>Randal Weber, MD</td>
<td>University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Matthew Witek, MD</td>
<td>University of Wisconsin Carbone Cancer Center</td>
</tr>
<tr>
<td>Gregory Wolf, MD</td>
<td>University of Michigan Rogel Cancer Center</td>
</tr>
<tr>
<td>Sue Yom, MD, PhD</td>
<td>UCSF Helen Diller Family Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Simon Yoo, MD</td>
<td>Lurie Cancer Center</td>
</tr>
</tbody>
</table>

This symposium is made possible, in part, by the generous endowed gift of Harry Staffileno, Jr., DDS, MS to support oncology-related oral health at Northwestern Medicine.

cancer.northwestern.edu/headneck

TARGET AUDIENCE
The target audience for this activity includes medical oncologists, radiation oncologists, surgical oncologists, fellows in training, oncology nurses, oral surgeons, dentists, speech pathologists and allied health professionals treating or interested in treating those with head and neck cancer.

ACCREDITATION STATEMENT
The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
The American Academy of Nurse Practitioners and the American Nurses Credentialing Center accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.